+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2022

  • ID: 5504277
  • Drug Pipelines
  • January 2022
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • AB Science
  • Acrivon Therapeutics
  • Aligos Therapeutics
  • Arbutus Biopharma
  • Cortexyme
  • Exscientia
This “Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Coronavirus-3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Coronavirus-3C-like-proteinase inhibitors Understanding

Coronavirus-3C-like-proteinase inhibitors: Overview


The 3C-like protease (3CLpro), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Coronavirus 3CLpro is a cysteine protease that has two N-terminal domains containing two β-barrel chymotrypsin-like folds (8-10). The active site of 3CLpro is located in the cleft between the two domains and is characterized by a catalytic Cys-His dyad. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Coronavirus-3C-like-proteinase inhibitors R&D. The therapies under development are focused on novel approaches for Coronavirus-3C-like-proteinase inhibitors.

Coronavirus-3C-like-proteinase inhibitors Emerging Drugs Chapters


This segment of the Coronavirus-3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Coronavirus-3C-like-proteinase inhibitors Emerging Drugs

PF 07321332: Pfizer

PF-07321332 is a SARS-CoV-2-3CL protease inhibitor being developed by Pfizer. Pfizer recently initiated a trial to test PF-07321332 for the Prevention of COVID-19. The phase II/III Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis (EPIC-PEP) trial will test PF-07321332 in up to 2,660 adults aged 18 and older who live in the same household as someone with a confirmed symptomatic COVID-19 infection. It is also being evaluated in another trial of symptomatic, non-hospitalized adult patients with COVID-19.

S-217622: Shionogi

S-217622 is a 3CL protease inhibitor discovered by Shionogi. SARS-CoV-2 has an enzyme called 3CL protease, which is essential for the duplication of the virus. S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease. In non-clinical trials using SARS-CoV-2 infected animals, it has been confirmed that the viral load is rapidly and significantly reduced. In the Japanese phase 1 clinical trial that just started, we will confirm the pharmacokinetics, safety and tolerability of this drug in healthy adults.

Coronavirus-3C-like-proteinase inhibitors: Therapeutic Assessment


This segment of the report provides insights about the different Coronavirus-3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players working on Coronavirus-3C-like-proteinase inhibitors


There are approx. 10+ key companies which are developing the Coronavirus-3C-like-proteinase inhibitors. The companies which have their Coronavirus-3C-like-proteinase inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, Pfizer.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Coronavirus-3C-like-proteinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Coronavirus-3C-like-proteinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Coronavirus-3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronavirus-3C-like-proteinase inhibitors drugs.

Coronavirus-3C-like-proteinase inhibitors Report Insights

  • Coronavirus-3C-like-proteinase inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Coronavirus-3C-like-proteinase inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions


Current Scenario and Emerging Therapies:

  • How many companies are developing Coronavirus-3C-like-proteinase inhibitors drugs?
  • How many Coronavirus-3C-like-proteinase inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coronavirus-3C-like-proteinase inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Coronavirus-3C-like-proteinase inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Coronavirus-3C-like-proteinase inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Pfizer
  • Shionogi
  • SyneuRx International (Taiwan) corp
  • AB Science
  • Sorrento Therapeutics
  • Acrivon Therapeutics
  • Exscientia
  • Arbutus Biopharma
  • Cortexyme
  • Aligos Therapeutics
  • SOM Biotech

Key Products

  • PF 07321332
  • S-217622
  • Pentarlandir
  • PF 07304814
  • MPI 8
  • Masitinib
  • MPI 1121
  • ACR 368
  • COR 803
  • ALG-097111
  • Eravacycline
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Acrivon Therapeutics
  • Aligos Therapeutics
  • Arbutus Biopharma
  • Cortexyme
  • Exscientia

IntroductionExecutive Summary
Coronavirus-3C-like-proteinase inhibitors: Overview
  • Structure
  • Mechanism of Action

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Coronavirus-3C-like-proteinase inhibitors - Analytical Perspective
Late Stage Products (Phase III and II/III)
  • Comparative Analysis

PF 07321332: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Pentarlandir: SyneuRx
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

S 217622: Shionogi
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

MPI 8: Sorrento Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Coronavirus-3C-like-proteinase inhibitors Key CompaniesCoronavirus-3C-like-proteinase inhibitors Key ProductsCoronavirus-3C-like-proteinase inhibitors- Unmet NeedsCoronavirus-3C-like-proteinase inhibitors- Market Drivers and BarriersCoronavirus-3C-like-proteinase inhibitors- Future Perspectives and ConclusionCoronavirus-3C-like-proteinase inhibitors Analyst ViewsCoronavirus-3C-like-proteinase inhibitors Key CompaniesAppendix
List of Tables
Table 1 Total Products for Coronavirus-3C-like-proteinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Coronavirus-3C-like-proteinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Pfizer
  • Shionogi
  • SyneuRx International (Taiwan) corp
  • AB Science
  • Sorrento Therapeutics
  • Acrivon Therapeutics
  • Exscientia
  • Arbutus Biopharma
  • Cortexyme
  • Aligos Therapeutics
  • SOM Biotech
Note: Product cover images may vary from those shown